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appendiceal neoplasms  [1, 13, 14, 21–24] . Mean age at 
diagnosis has been reported between 38 and 51 years  [6, 
24–26] . However, appendiceal NEN have also been re-
ported in pediatric patients between 4.5 and 19.5 years of 
age  [2, 4, 17, 27–29] , but population-based data are not 
available for this special subgroup.
 The prognosis of the majority of appendiceal NEN is 
excellent in the series that report outcome on lower tu-
mor stages with 5-year survival rates (YSR) of 100% or 
close to this  [7, 14, 11, 25, 30–32] . However, the whole 
cohort including all tumor stages does not show such a 
favorable prognosis, with 5-YSR ranging between 70 and 
85%  [11, 25, 30, 31, 33] . Advanced stages with distant me-
 Epidemiology and Prognosis 
 Neuroendocrine neoplasms (NEN) of the appendix 
are a relatively frequent subgroup of NEN with an ap-
proximate incidence rate of 0.15–0.6/100,000/year and 
with a slight female preponderance in Western series  [1–
12] . Although NEN are frequently reported  [13] , most 
cases are of an early stage  [12–14] . The reported incidence 
has increased in more recent years  [1, 6] ; however, the 
overall incidence rate is probably roughly within the same 
range between different races, although some differences 
have been reported  [1, 12, 15–18] . Furthermore, common 
practice in performing appendicectomies may also influ-
ence the reported incidence of appendiceal NEN  [19, 20] .
 Appendiceal NEN comprise the largest subgroup of 
appendiceal neoplasms with approximately 30–80% of all 
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tastases have been reported with a much poorer progno-
sis and a 5-YSR of as low as 12–28%  [1, 11, 14] . However, 
it is not clear to which extent more ‘malignant’ histologies 
such as goblet cell carcinoids (GCC) or mixed adenoneu-
roendocrine carcinomas with a poorer prognosis per se 
were included in such series.
 Minimal Consensus Statement on Epidemiology and 
Prognosis 
 Appendiceal NEN present with an incidence of 0.15–
0.6/100,000/year. They are diagnosed slightly more often in fe-
male than in male patients at an average age of 40–50 years. Ap-
pendiceal NEN are, however, much more frequently diagnosed 
incidentally during appendicectomy with a rate of approximate-
ly 3–5/1,000 appendicectomies. Racial differences may occur but 
data are inconclusive. In contrast, malignant tumors seem to oc-
cur more often in Caucasians compared to other races. Appen-
diceal NEN may also rarely occur in children but apparently with 
an excellent long-term outcome. While at a lower stage, survival 
is extremely good (local disease: 5-YSR of 95–100%, regional dis-
ease: 5-YSR of 85–100%), on the other hand, the few cases with 
distant metastasis present with relatively poor survival figures 
(5-YSR: <25%).
 From the available data, it is concluded that an appendiceal 
NEN <1 cm, with invasion up to the subserosa or mesoappendi-
ceal invasion up to 3 mm and clear surgical margins poses no 
further risk of recurrence after appendicectomy.
 Most tumors (70%) are located at the tip of the appendix. 
However, tumors at the base of the appendix, tumors of 1–2 cm 
in diameter and tumors with deep mesoappendiceal invasion or 
margin invasion confer a relevant risk of recurrence, and further 
surgical procedures are warranted, although no data have liter-
ally proven a survival benefit of more aggressive surgery.
 Clinical Presentation 
 Most appendiceal NEN in adults as well as in chil-
dren are incidental findings in postappendicectomy 
specimen and therefore no characteristic tumor-specif-
ic symptomatology has been established  [5, 17] . How-
ever, symptoms that lead to appendicectomy such as 
right lower abdominal pain are indirectly associated 
with appendiceal NEN, although due to their most fre-
quent localization at the tip of the appendix (approx. 
70%) these tumors are very likely not causative of acute 
appendicitis  [34–41] . In the rare cases of distant metas-
tases, these may cause symptoms related to the localiza-
tion of the metastases.
 A carcinoid syndrome is an extreme exception in met-
astatic patients  [35, 36, 38] and more likely associated 
with an intestinal primary tumor.
 Minimal Consensus Statement on Clinical 
Presentation 
 Appendiceal NEN are rarely symptomatic in the large major-
ity of cases due to the incidental nature of their diagnosis. How-
ever, tumors with extensive local disease or distant metastases 
may appear symptomatic with abdominal pain, a tumor mass 
effect or signs of bowel obstruction. An association with the car-
cinoid syndrome is extremely rare and indicates metastatic dis-
ease.
 Diagnostic Procedures 
 Since most appendiceal NEN are incidentally diag-
nosed during postoperative histology, diagnostic proce-
dures relate mostly to postoperative staging, follow-up 
and to the rare cases with suspected or evidenced distant 
metastasis.
 Imaging 
 There are no specific diagnostic studies focusing on 
appendiceal NEN only, and therefore the considerations 
which apply to small intestinal NEN are considered to be 
also valid for appendiceal NEN and have not been changed 
since the previous version of the guidelines.
 Cross-sectional imaging using CT or MRI with mod-
ern protocols should be used to rule out locoregional or 
distant metastasis  [42–45] . NEN limited to the appendix 
may be detected by transabdominal ultrasonography, 
which in spite of its investigator-dependent limitations is 
the least invasive procedure but has not been validated. 
Endoscopy is rarely helpful, unless the tumor is locally 
advanced and infiltrates the cecum, which is a very rare 
situation; thus, colonoscopy for tumor detection is not 
recommended  [46] . In the context of the potentially in-
creased incidence of secondary neoplasms, general rec-
ommendations regarding colorectal cancer screening 
should be followed. Somatostatin receptor imaging using 
either indium-111-somatostatin receptor scintigraphy 
(including SPECT) or positron emission tomography 
(PET) scanning using gallium-68-labelled somatostatin 
analogues in combination with CT may be considered in 
cases where curative resection is not completely assured 
or where distant metastasis is suspected  [45] .
 Laboratory Tests 
 Chromogranin A (CgA) can be used as a tumor mark-
er in appendiceal NEN like in small intestinal NEN and 
is particularly useful to differentiate NEN from GCC 
since it has been described to be increased in appendiceal 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
ts
bi
bl
io
th
ek
 B
er
n 
   
   
   
   
   
   
   
   
   
   
   
   
  
13
0.
92
.9
.5
5 
- 6
/8
/2
01
6 
4:
39
:3
8 
PM
 Pape   et al.
 
 Neuroendocrinology 2016;103:144–152 
DOI: 10.1159/000443165
146
NEN  [47, 48] . However, its role for regular follow-up 
(particularly for the detection of recurrent disease) has 
not been thoroughly studied. It is indicated in metastatic 
disease as a follow-up parameter like in other NEN. In the 
extremely rare patient with carcinoid syndrome, urinary 
5-HIAA may be useful  [49] .
 Minimal Consensus Statement on Diagnostic 
Procedures 
 For the majority of well-differentiated appendiceal NEN di-
agnosed incidentally, with a maximum diameter <1 cm and R0 
resection, no postoperative diagnostic procedure is required. For 
well-differentiated tumors of 1 to <2 cm and R0 resection, there 
are no clear data, but a single CT or MRI of the abdomen to rule 
out lymph node or distant involvement may be justified. In cases 
with deep mesoappendiceal infiltration or angioinvasion and tu-
mors >2 cm, CT or MRI of the abdomen and somatostatin recep-
tor imaging (somatostatin receptor scintigraphy or SR-PET/CT) 
should be performed.
 CgA may be used as a surrogate parameter in advanced met-
astatic appendiceal NEN but has not been particularly validated 
for diagnosis and follow-up of appendiceal NEN.
 Pathology and Genetics 
 The histopathological characterization of appendiceal 
NEN includes immunohistochemical proof of the neuro-
endocrine tumor (NET) entity by immunohistochemical 
staining for synaptophysin and CgA as well as for Ki-67 
to determine the proliferative capacity of the tumor  [50–
52] .
 The Ki-67 index also determines the tumor grading 
according to the current WHO classification ( table 1 )  [50, 
52] . NEN of the appendix are usually G1 or G2 (Ki-67 in-
dex <20%) and thus should be considered NET  [53] . Ap-
pendiceal G2 NET are considered to comprise a higher 
risk of recurrence and/or metastasis; however, direct 
proof of this is still pending and has in fact been chal-
lenged  [54] . Besides WHO grading TNM staging accord-
ing to either the UICC/AJCC classification or ENETS 
guidelines (or best according to both; table 2) is recom-
mended  [52, 53, 55, 56] .
 In cases of higher tumor grades, one should indeed 
suspect either a GCC or mixed adenoneuroendocrine 
carcinoma, but rare cases of a ‘true’ neuroendocrine car-
cinoma (G3 NEC) may occur. Neither is considered a 
NET, and thus beyond the scope of these guidelines. The 
management of these neoplasms should be tailored to the 
respective adenocarcinomas  [46, 56, 66] .
 Stratification according to Size, Localization and 
Extent of Invasion 
 There are no substantial changes of criteria used for 
stratifying therapeutic decision in appendiceal NEN since 
the 2011 guidelines. Thus, for an extensive discussion, 
this chapter refers the reader to the previously published 
guidelines and just summarizes the key criteria a care-
giver should have available for the therapeutic decision 
 [46] .
 Summary of the Main Prognostic Features of 
Appendiceal NEN 
 (A) Size 
 – Tumors <1 cm (T1a according to the UICC/AJCC classifica-
tion and T1 according to the ENETS guidelines;  table 2 ) can 
be cured by simple appendicectomy with an excellent almost 
100% long-term survival rate in both children and adults  [5, 
27, 28, 37, 57] , although some publications have described 
lymph node metastasis  [14, 19] while others have not  [38, 58] . 
 – Tumors >1 cm but <2 cm (T1b according to the UICC/AJCC 
classification and T2 according to the ENETS guidelines;  ta-
ble 2 ) are most challenging for decision making, because me-
tastases seem to occur only rarely in this subgroup, but the 
subgroup per se comprises 5–25% of all appendiceal NEN. 
However, a risk of metastasis seems to exist, particularly in 
cases >1.5 cm  [5, 7, 14, 19, 41, 54, 57–59] . 
 – Tumors >2 cm are rare (<10%) but may carry a risk of metas-
tasis of up to 40%  [7, 37, 58] and, therefore, justify a radical 
oncological resection and long-term follow-up (T2 according 
to the UICC/AJCC classification and T3 according to the
ENETS guidelines;  table 2 ). Metastasis has been observed in 
some cases of these appendiceal NET  [58] but not in all  [60] . 
 – Tumors extending beyond the appendix invading the perito-
neum or adjacent organs (T4 according to the UICC/AJCC 
classification and the ENETS guidelines;  table 2 ), infiltrating 
lymph nodes (N1 according to the UICC/AJCC classification 
and the ENETS guidelines;  table 2 ) or metastasizing to distant 
organs (M1 according to the UICC/AJCC classification and 
the ENETS guidelines;  table 2 ) are no longer considered a lim-
ited disease and require systemic oncological evaluation be-
cause of poorer long-term outcome  [46, 53, 56] . 
 Table 1.  Grading classification of NEN according to the WHO 
2010 classification
Grading Ki-67 index Mitotic rate
G1 NET ≤2% <2/10 HPF
G2 NET 3 – 20% 2 – 20/10 HPF
G3 NEC >20% >20/10 HPF
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 (B) Localization within the Appendix 
 Most appendiceal NEN are located at the tip of the organ (60–
75%), while some are located at the middle portion (5–20%) and 
the smallest fraction (<10%) at the base of the appendix. Al-
though there is no clear correlation with outcome, incomplete 
resection resulting in recurrence and metastases may likely occur 
more frequently with an appendiceal NET located next to or at 
the base of the appendix  [37, 46, 56] .
 (C) Extent of Invasion into the Mesoappendix and Vascular 
Invasion 
 Tumor cell invasion into the mesoappendix (T2 vs. T3 stage 
according to the ENETS guidelines, not considered by the UICC/
AJCC classification; see  table 2 ) can relatively frequently be ob-
served in up to 20% of adults and up to 40% of children  [27, 61, 
62] . While an infiltration of the appendiceal serosa does not seem 
to be associated with poorer outcome, an invasion into the me-
soappendix shows a higher rate of vascular (V1) or lymph vessel 
involvement (L1) than in cases without. Furthermore, an inva-
sion depth of >3 mm has been suggested to reflect the aggressive-
ness of the disease. Therefore, the TNM classification by the
ENETS uses this criterion to distinguish T2 from T3 tumors 
(even in case of tumors <2 cm)  [52] .
 The pathology report should therefore contain: pTNM stage, 
WHO grading, vascular (V0/1) or lymph (L0/1) vessel involve-
ment and a statement on mesoappendiceal infiltration (and the 
extent of the latter).
 These criteria or risk factors can then be used as a logical and 
likely but hitherto formally unproven rationale for decision mak-
ing of whether a right-sided hemicolectomy should be recom-
mended or whether it seems likely safe to not do so ( fig. 1 ).
 Minimal Consensus Statement on Pathology and 
Genetics 
 A histological analysis is always necessary to establish the di-
agnosis. Cytology may be helpful, particularly in the rare meta-
static setting. The minimal ancillary tests to support the histo-
logical diagnosis include immunohistochemistry for CgA and 
synaptophysin. Both the mitotic count per 10 HPF (2 mm 2 , at 
least 40 fields at 40× magnification), evaluated in areas of highest 
mitotic density, and the Ki-67 index (MIB1 antibody; percentage 
of 2,000 cells in areas of highest nuclear labeling) should be re-
ported ( table 1 ). The histopathology report should allow for a 
correct classification according to the current WHO criteria.
 The ENETS TNM staging differs for the T stages from the 
AJCC/UICC/WHO TNM staging for appendiceal tumors. It is 
strongly recommended to use the ENETS TNM classification in 
addition to the AJCC/UICC/WHO system and to indicate this in 
the pathology report ( table 2 ). Furthermore, vascular and lymph 
node involvement should be stated as aides to clinical decision 
making ( fig. 1 ). No genetic association has been reported thus far 
and, therefore, there is currently no need for any genetic testing.
 Table 2. TNM staging for appendiceal NEN according to either the ENETS guidelines or the UICC/AJCC classification
ENETS guidelines UICC/AJCC classification
T – primary tumor
x primary tumor not assessed/assessable
0 no evidence of any primary tumor
1 tumor ≤1 cm with infiltration of the submucosa and muscularis 
propria
1a tumor ≤1 cm
1b tumor >1 cm but ≤2 cm
2 tumor ≤2 cm with infiltration of the submucosa, muscularis 
propria and/or minimal (≤3 mm) infiltration of the subserosa 
and/or mesoappendix
tumor >2 cm but ≤4 cm or with 
extension into the cecum
3 tumor >2 cm and/or extensive (>3 mm) infiltration of
the subserosa and/or mesoappendix
tumor >4 cm or with extension into the 
ileum
4 tumor with infiltration of the peritoneum and/or other 
neighboring organs
tumor with perforation of the 
peritoneum or invasion of other adjacent 
structures
N – regional lymph node metastasis
Nx regional lymph nodes not assessed/assessable
N0 no regional lymph node metastasis
N1 locoregional lymph node metastasis/-es
M – distant metastasis
Mx distant metastasis not assessed/assessable
M0 no distant metastasis
M1 distant metastasis/-es
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 Surgical Therapy 
 Two surgical procedures can be applied to treat local 
or locoregional appendiceal NEN: simple appendicecto-
my and oncological right-sided hemicolectomy.
 As outlined above, appendiceal NEN are frequently di-
agnosed incidentally at appendicectomy for suspected or 
manifest acute appendicitis. The NEN may either be al-
ready detected during this procedure or afterwards on 
histological evaluation. Similar to the staging criteria in-
cluding the risk factors mentioned above, the surgical 
strategy should be tailored to the individual situation 
( fig. 1 ) and according to the data discussed in the section 
above. In general, the following statements apply to the 
specific situations:
 1 Appendiceal NET (G1/2) <2 cm can be cured by sim-
ple appendicectomy unless incompletely resected or if 
any of the below discussed additional situations occurs 
in which right-sided hemicolectomy should be consid-
ered or performed (R1 resection status after initial ap-
pendicectomy). 
2  Appendiceal NET (G1/2) >2 cm should be treated with 
oncological right-sided hemicolectomy. However, 
small G1/2 NET appear to be the most frequently ob-
served clinical situation and, therefore, the arguments 
for decision making are specified as follows: 
 • T1 (ENETS) or T1a (UICC/AJCC) NET (i.e. <1 cm): 
generally, simple appendicectomy is curative and suf-
ficient (if the resection status is R0). The only excep-
tion could be the extremely rare situation when the 
NEN is located at the base of the appendix or when a 
mesoappendiceal invasion >3 mm is discovered histo-
pathologically. Under these circumstances, a comple-
tion of the resection seems advisable, although a worse 
prognosis has not been proven and a higher complica-
tion rate than with simple appendicectomy has to be 
considered  [5, 7, 14, 19, 41, 54, 57, 59] . 
 • T2 (ENETS) or T1b (UICC/AJCC) NET (i.e. >1 cm but 
<2 cm): lymph node or distant metastasis seems un-
likely but possible, since it has been reported several 
times. Thus, long-term definitive cure can be achieved 
with a right-sided hemicolectomy; however, increased 
peri- and postoperative morbidity need to be weighed 
against the small but existing risk of incomplete resec-
tion by appendicectomy or late recurrence (particu-
larly in many relatively young patients). This risk may 
be higher if the tumor size is >1.5 cm, particularly in 
children, but evidence is too weak to exclude patients 
with appendiceal NET <1.5 cm from these consider-
ations. 
 Additional risk factors have been defined for assisting 
in decision making under these circumstances: 
Appendicectomy
tip/middle
and R0*
Location base
or R1
No risk factors***
* ‘no tumor on margin’
** very limited evidence
*** Risk factors:
• V1
• L1
• G2
• >3 mm infiltration
of mesoappendix
If risk factors***, discuss
tip/middle
and R0
base
or R1
Treatment finished
Right-sided hemicolectomy
(incl. lymph nodes)
Appendicectomy
? ENETS? UICC/AJCC? ENETS? UICC/AJCC? ENETS? UICC/AJCC?
Size? <1? cm? ?1?cm? 1–2?cm? 1–2?cm? >2? cm? 2–4?cm?
T?class? T1? T1a? T2? T1b? T3? T2?(or?>)?
?????????????????
mesoappendix?
?????????? 0?
?
?
–?
?
?
<?3 mm**?
?
?
–?
?
?
>3? mm**?
?
?
–?
 Fig. 1. Therapeutic algorithm for small
appendiceal NET. V1 = Vascular invasion;
L1 = lymphatic invasion; G2 = grade 2 tu-
mor (Ki-67: 3–20%). 
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 – WHO grading: G2
 – Vascular (V1) or lymph vessel (L1) invasion
 – Mesoappendiceal infiltration >3 mm
 If one or more of these risk factors coexist, it is recom-
mended to discuss right-sided hemicolectomy with the 
patients.  
 • T3 (ENETS) or T2 (UICC/AJCC) or higher-stage NET 
(i.e. >2 cm): right-sided hemicolectomy with oncolog-
ical lymph node dissection is advised due to the clear-
ly increased risk of lymph node metastasis and long-
term tumor recurrence and/or distant metastasis. The 
operation can be performed as the initial surgical in-
tervention or as a second intervention after initial (di-
agnostic) appendicectomy  [60] . 
 • Appendiceal NEC (G3, Ki-67 >20%) should, irrespec-
tive of the tumor size, be treated using an oncological 
right-sided hemicolectomy and be managed as adeno-
carcinoma cases. 
3  In pediatric patients, outcome after appendiceal NET 
resection has been extremely favorable in the group 
with tumors between 1 and 2 cm and even in those 
with tumors >2 cm, and thus these guidelines explic-
itly do not apply to this specific population. The reason 
for the even better outcome in the pediatric population 
is currently not understood  [5, 63] . 
 Minimal Consensus Statement on Surgical Therapy 
 It is generally felt that a well-differentiated appendiceal NEN 
<2 cm is cured by appendicectomy independent of the location 
of the tumor. Thus, right-sided hemicolectomy is justified only 
in those rare tumors measuring 1–2 cm but with positive or un-
clear margins or with deep mesoappendiceal invasion (ENETS 
T2), higher proliferation rate (G2) and/or vascular invasion. Tu-
mors with a diameter >2 cm should be treated by right-sided 
hemicolectomy.
 Follow-Up 
 In cases of curative resection of appendiceal NEN <1 
cm by simple appendicectomy, no specific follow-up 
strategy has been recommended  [46, 64] . For cases with 
right-sided hemicolectomy due to a size >1 cm but with-
out proof of lymph node involvement or any other re-
sidual disease in the resected specimen, again no specific 
follow-up strategy seems to be necessary  [65] . For cases 
with involvement of the lymph nodes or any cases with 
resected distant metastases, however, long-term follow-
up is advised because of the proven invasiveness of the 
tumor. Finally, in patients with an appendiceal NEN mea-
suring between 1 and 2 cm who have not received right-
sided hemicolectomy for whatever reason (comorbidity, 
no consent, hesitancy, etc.) but with risk factors (i.e. lo-
calization at the base of the appendix, mesoappendiceal 
invasion >3 mm, G2 NET or vascular invasion), regular 
follow-up seems advisable due to the presumed risk of 
lymph node metastasis but any benefit for the prevention 
of tumor recurrence or an influence on long-term out-
come is unproven  [65] . It should be considered that nei-
ther the determination of surrogate parameters (i.e. CgA 
or 5-HIAA) nor indirect noninvasive imaging have been 
studied for their sensitivity for detecting metastasis or lo-
cal tumor recurrence in this specific setting. Cumulative 
exposure to irradiation with repetitive scanning may be 
an argument to use MRI rather than CT scanning in 
younger and particularly in fertile patients (female or 
male)  [45] . The role of colonoscopy or transabdominal 
ultrasound has not been established in this setting and is 
not recommended. However, it seems rational to apply 
transabdominal ultrasound to extend the intervals be-
tween MRI or CT examinations. Although unproven, the 
life-long awareness of the potential of these slowly grow-
ing tumors to recur should be kept in mind in appendiceal 
NEN >2 cm or >1 cm with risk factors  [46, 64] .
 Minimal Consensus Statement on Follow-Up 
 For guidelines regarding follow-up strategies, we recommend 
to follow the ENETS standards of care  [64] .
 For well-differentiated tumors, diagnosed incidentally, with a 
maximum diameter of <1 cm and R0 resection, no follow-up is 
required.
 For well-differentiated tumors of 1–2 cm and R0 resection, 
there are no sufficient data for a clear-cut decision. Most partici-
pants at the Consensus Conference suggested no regular follow-
up. However, in cases with risk factors, follow-up may be consid-
ered, although a specific schedule is not recommended.
 All other patients, with either tumors >2 cm, metastasis or 
additional risk factors (R1 resection), should be followed initial-
ly after 6 and 12 months postoperatively and then annually, al-
though this approach has also not been validated.
 Please also refer to the consensus guideline updates for 
other gastroenteropancreatic NET [ 67–72 , this issue].
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